Updating results

577 results

Sort: Relevance | Date

Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab [ID981]

In development [GID-TA10107] Expected publication date: 20 November 2019

Technology appraisal guidance In development

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

In development [GID-TA10458] Expected publication date: TBC

Technology appraisal guidance In development

Chronic kidney disease: assessment and management (update)

In development [GID-NG10118] Expected publication date: 18 March 2021

NICE guideline In development

Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]

In development [GID-TA10508] Expected publication date: TBC

Technology appraisal guidance In development

Rehabilitation in adults with complex psychosis and related severe mental health conditions

In development [GID-NG10092] Expected publication date: 19 June 2020

NICE guideline In development

Selective internal radiation therapies for treating hepatocellular carcinoma ID1276

In development [GID-TA10381] Expected publication date: TBC

Technology appraisal guidance In development

Human and animal bites: antimicrobial prescribing

In development [GID-NG10137] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Vaccine uptake in the general population

In development [GID-NG10139] Expected publication date: 19 October 2021

NICE guideline In development

Mental wellbeing at work

In development [GID-NG10140] Expected publication date: 18 August 2021

NICE guideline In development

Acute coronary syndromes

In development [GID-NG10085] Expected publication date: 30 July 2020

NICE guideline In development

Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

In development [GID-TA10122] Expected publication date: TBC

Technology appraisal guidance In development

Lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies ID1444

In development [GID-TA10477] Expected publication date: TBC

Technology appraisal guidance In development

Behaviour change: digital and mobile health interventions

In development [GID-NG10101] Expected publication date: 05 August 2020

NICE guideline In development

Electrical stimulation to improve muscle strength in non-neurological chronic conditions

In development [GID-IPG10135] Expected publication date: TBC

Interventional procedures guidance In development

MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy

In development [GID-IPG10122] Expected publication date: 26 February 2020

Interventional procedures guidance In development

ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

In development [GID-TA10489] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 [ID943]

In development [GID-HST10008] Expected publication date: 27 November 2019

Highly specialised technologies guidance In development

Skin tumours including Melanoma: assessment and management

In development [GID-NG10155] Expected publication date: 04 April 2022

NICE guideline In development

Cannabidiol for adjuvant treatment of seizures associated with Dravet syndrome [ID1211]

In development [GID-TA10274] Expected publication date: 18 December 2019

Technology appraisal guidance In development

Cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome [ID1308]

In development [GID-TA10410] Expected publication date: 18 December 2019

Technology appraisal guidance In development

Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis

In development [GID-IPG10117] Expected publication date: TBC

Interventional procedures guidance In development

Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues

In development [GID-IPG10063] Expected publication date: TBC

Interventional procedures guidance In development

Specialist neonatal respiratory care for babies born preterm

In development [GID-QS10137] Expected publication date: 20 March 2020

Quality standard In development

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508]

In development [GID-TA10421] Expected publication date: 05 February 2020

Technology appraisal guidance In development

Community pharmacies: promoting health and wellbeing

In development [GID-QS10115] Expected publication date: 02 June 2020

Quality standard In development

Faltering growth

In development [GID-QS10083] Expected publication date: 02 June 2020

Quality standard In development

Endo-Sponge for treating colorectal anastomotic leakage

In development [GID-MT539] Expected publication date: 01 September 2020

Medical technologies guidance In development

Danis Stent for acute oesophageal variceal bleeds

In development [GID-MT537] Expected publication date: 06 October 2020

Medical technologies guidance In development

Atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer [ID1522]

In development [GID-TA10433] Expected publication date: TBC

Technology appraisal guidance In development

Caesarean section (Update)

In development [GID-NG10081] Expected publication date: 21 January 2021

NICE guideline In development

Inducing labour (Update)

In development [GID-NG10082] Expected publication date: 01 July 2020

NICE guideline In development

Depression in adults: treatment and management

In development [GID-CGWAVE0725] Expected publication date: TBC

NICE guideline In development

Rehabilitation after Traumatic injury

In development [GID-NG10105] Expected publication date: 04 August 2021

NICE guideline In development

Pelvic floor dysfunction: prevention and non-surgical management

In development [GID-NG10123] Expected publication date: 26 August 2021

NICE guideline In development

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2019)

In development [GID-NG10087] Expected publication date: 30 March 2020

NICE guideline In development

Looked-after children and young people

In development [GID-NG10121] Expected publication date: 26 April 2021

NICE guideline In development

Decision-making and mental capacity

In development [GID-QS10127] Expected publication date: 31 March 2020

Quality standard In development

Renal and ureteric stones

In development [GID-QS10095] Expected publication date: 16 April 2020

Quality standard In development

Leg ulcer infection: antimicrobial prescribing

In development [GID-NG10133] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Impetigo: antimicrobial prescribing

In development [GID-NG10134] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Insect bites and stings: antimicrobial prescribing

In development [GID-NG10136] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Clostridium difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 30 September 2020

Antimicrobial prescribing guideline In development

Social, emotional and mental wellbeing in primary and secondary education

In development [GID-NG10125] Expected publication date: 28 May 2021

NICE guideline In development

Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma [ID1081]

In development [GID-TA10171] Expected publication date: TBC

Technology appraisal guidance In development

NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)

In development [GID-TA10183] Expected publication date: TBC

Technology appraisal guidance In development

Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

In development [GID-TA10180] Expected publication date: TBC

Technology appraisal guidance In development

Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

In development [GID-TA10177] Expected publication date: TBC

Technology appraisal guidance In development

Eculizumab for treating refractory myasthenia gravis [ID1064]

In development [GID-TA10176] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated multiple myeloma (ID1139)

In development [GID-TA10193] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228

In development [GID-TA10203] Expected publication date: TBC

Technology appraisal guidance In development